Table 2 Intracranial efficacy of alectinib in three cohorts

CNS ORR in all cohort patients (%)

55%

[95% CI: 31.5–76.9%]

(11/20)

53%

[95% CI: 34.7–74.9%]

(17/32)

38.5%

[95% CI: 13.9–68.4%]

(5/13)

CNS ORR in patients with CNS target lesions (%)

82%

[95%CI:48.2%-97.7%]

(9/11)

76.5%

[95% CI: 50.1–93.2%]

(13/17)

43%

[95% CI: 9.9–81.6%]

(3/7)

Median intracranial tumor shrinkage rate

53%

Range 0, 100%

58%

Range 14%, 100%

28%

Range 0, 100%